ReviewArthritis research & therapy2006
Epidemiology, risk factors, and lifestyle modifications for gout.
Review in Arthritis research & therapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
97 citing papers in PubMed, 5 syntheses or guidelines pooled it, 262 citations in OpenAlex.
- Pooled it
- Pooled it
- Determinants of the prevalence of gout in the general population: a systematic review and meta-regression.European journal of epidemiology · 2015Pooled it
- "Clinical features of women with gout arthritis." A systematic review.Clinical rheumatology · 2010Pooled it
- Pegloticase for chronic gout.The Cochrane database of systematic reviews · 2010Pooled it
- A pilot study of IL-1 inhibition by anakinra in acute gout.Arthritis research & therapy · 2007Trial
- Associations between dietary factors and serum uric acid levels in Korean women aged 19-65 years.Nutrition research and practice · 2026Article
- Epidemiological trends and burden of gout in China and the European Union: a GBD 2023 and Mendelian randomization study.Clinical rheumatology · 2026Article
- Observational
- Sex-specific DNA methylation associations with circulating urate levels and BCG-induced urate changes.Communications medicine · 2025Article
- The anti-hyperuricemia potential of bioactive natural products and extracts derived from traditional Chinese medicines: A review and perspective.Journal of pharmaceutical analysis · 2025Review
- Pacific community's perceptions on how to improve uptake of urate-lowering therapy for Pacific gout patients.International journal for equity in health · 2025Article
- Case Report: Intradural gout tophi without systemic gout symptoms.Frontiers in surgery · 2025Article
- Association Between Abdominal Obesity and Hyperuricemia in Peruvian Adults with Type 2 Diabetes Mellitus.Clinical medicine insights. Endocrinology and diabetes · 2025Article
- Global, regional, and national burden of gout in elderly 1990-2021: an analysis for the global burden of disease study 2021.BMC public health · 2024Article
- Development and validation of a knowledge, attitude, and practice questionnaire regarding exercise and exergames for obese patients with gout.BMC public health · 2024Article
- Global, regional, and national burden of gout, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021.The Lancet. Rheumatology · 2024Article
- Clinical characteristics and risk factors associated with bone erosion in patients with tophi.Advances in rheumatology (London, England) · 2024Article
- The Impact of Different Intensities of Physical Activity on Serum Urate and Gout: A Mendelian Randomization Study.Metabolites · 2024Article
- The Evolving Landscape of Gout in the Female: A Narrative Review.Gout, urate, and crystal deposition disease · 2023Article
37 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gout affects more than 1% of adults in the USA, and it is the most common form of inflammatory arthritis among men. Accumulating data support an increase in the prevalence of gout that is potentially attributable to recent shifts in diet and lifestyle, improved medical care, and increased longevity. There are both nonmodifiable and modifiable risk factors for hyperuricemia and gout. Nonmodifiable risk factors include age and sex. Gout prevalence increases in direct association with age; the increased longevity of populations in industrialized nations may contribute to a higher prevalence of gout through the disorder's association with aging-related diseases such as metabolic syndrome and hypertension, and treatments for these diseases such as thiazide diuretics for hypertension. Although gout is considered to be primarily a male disease, there is a more equal sex distribution among elderly patients. Modifiable risk factors for gout include obesity, the use of certain medications, high purine intake, and consumption of purine-rich alcoholic beverages. The increasing prevalence of gout worldwide indicates that there is an urgent need for improved efforts to identify patients with hyperuricemia early in the disease process, before the clinical manifestations of gout become apparent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.